Method for treating pancreatitis
Gemcabene, a carboxyalkylether, is effective in the treatment and prevention of pancreatitis in subjects. The compound can be administered in an effective dose as the free acid, a pharmaceutically acceptable salt, or an ester or pro-drug that is hydrolyzed or otherwise metabolized in situ to gemcabene as the free acid or salt thereof.
1. A method of decreasing a subject's risk for developing pancreatitis comprising administering to a subject in need thereof, an effective dose of a compound
or a salt thereof, wherein the subject is a human and has a blood triglyceride level of 500 mg/dl or higher.
2. The method according to claim 1 , wherein the subject has a LDL-cholesterol level greater than 100 mg/dL.
3. The method according to claim 1 , wherein the amount of the compound administered is between about 100 mg/day and about 900 mg/day.
4. The method according to claim 1 , wherein the amount of the compound administered is 150 mg/day, 300 mg/day, or 600 mg/day.
5. The method according to claim 1 , wherein the amount of the compound administered is 150 or 300 mg/day.
6. The method according to claim 3 , wherein the compound is administered once daily.
7. The method according to claim 1 , wherein the compound is administered in combination with an agent selected from: a cholesterol lowering agent, a cholesterol absorption inhibitor, a bile acid sequestrant, an ApoB synthesis inhibitor, or a protease inhibitor.
8. The method according to claim 7 , wherein the agent is a statin.
9. The method according to claim 1 , wherein the compound is the nionocalcium salt
10. The method according to claim 9 , wherein the subject has LDL-cholesterol level greater than 100 mg/dL.
11. The method according to claim 10 , wherein the amount of the compound administered is between about 100 mg/day and about 900 mg/day.
12. The method according to claim 9 , wherein the amount of the compound administered is 150 mg/day, 300 mg/day, or 600 mg/day.
13. The method according to claim 9 , wherein the amount of the compound administered is 150 or 300 mg/day.
14. The method according to claim 11 , wherein the compound is administered once daily.
15. The method according to claim 9 , wherein the compound is administered in combination with an agent selected from: a cholesterol lowering agent, a cholesterol absorption inhibitor, a bile acid sequestrant, an ApoB synthesis inhibitor, or a protease inhibitor.
16. The method according to claim 15 , wherein the agent is a statin.